AnnJi Pharmaceutical Unveils Promising Clinical Results for AJ201 at WMS 2025 AnnJi Pharmaceutical's AJ201 shows positive clinical trial results for SBMA at the World Muscle Society 2025, signaling hope for patients.

AnnJi Pharmaceutical Unveils Promising Clinical Results for AJ201 at WMS 2025 #None #AJ201 #SBMA #AnnJi

AnnJi Pharmaceutical Announces Breakthrough Results of AJ201 for Spinal and Bulbar Muscular Atrophy AnnJi Pharmaceuticals has revealed promising Phase 2a clinical trial results for AJ201 targeted at Spinal and Bulbar Muscular Atrophy, presented at WMS 2025.

AnnJi Pharmaceutical Announces Breakthrough Results of AJ201 for Spinal and Bulbar Muscular Atrophy #Taiwan #Taipei #AJ201 #SBMA #AnnJi

AnnJi Pharmaceutical Unveils Promising Clinical Results for AJ201 at the 2025 World Muscle Society Congress AnnJi Pharmaceutical showcased the encouraging Phase 2a results for AJ201, a potential treatment for spinal bulbar muscular atrophy, at the WMS 2025 Congress.

AnnJi Pharmaceutical Unveils Promising Clinical Results for AJ201 at the 2025 World Muscle Society Congress #Taiwan #Taipei #AJ201 #SBMA #AnnJi

AnnJi Pharmaceutical Reveals Phase 2a Breakthrough of AJ201 for SBMA at WMS 2025 AnnJi Pharmaceutical highlighted Phase 2a results of AJ201 for spinal and bulbar muscular atrophy at WMS 2025, indicating a major step forward.

AnnJi Pharmaceutical Reveals Phase 2a Breakthrough of AJ201 for SBMA at WMS 2025 #Taiwan #Taipei #AJ201 #SBMABio #AnnJi